242 results on '"Selroos, Olof"'
Search Results
2. The Finnish experience to save asthma costs by improving care in 1987-2013
3. List of Contributors
4. A Population Management Model of Asthma and Allergy
5. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?
6. Budesonide/Formoterol Easyhaler®: Performance Under Simulated Real-Life Conditions
7. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study
8. Comparison of efficiency of bambuterol and salmeterol
9. Inhaler Competence and Patient Satisfaction with Easyhaler®: Results of Two Real-Life Multicentre Studies in Asthma and COPD
10. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?
11. Dry-powder inhalers in acute asthma
12. Performance of Turbuhaler® in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma: Understanding the Clinical Importance of Adequate Peak Inspiratory Flow, High Lung Deposition, and Low In Vivo Dose Variability
13. Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children—not too much, not too little
14. Exome Sequencing Identifies Susceptibility Loci for Sarcoidosis Prognosis
15. Differences in Sarcoidosis Around the World
16. Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
17. ACE gene variants and sarcoidosis in a Finnish population
18. Ophthalmologic findings in children with asthma receiving inhaled budesonide
19. Delivery Devices for Inhaled Asthma Medication: Clinical Implications of Differences in Effectiveness
20. Some Aspects on Comparative Efficacy Studies with Inhaled Corticosteroids in Asthma
21. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
22. Chapter 1 - A Population Management Model of Asthma and Allergy: Case Finland
23. No Evidence of Glucocorticosteroid-induced Apoptosis of Airway Epithelial Cells In Vivo
24. Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function*
25. Efficacy of budesonide Turbuhaler® compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma
26. Comparison of a beta-2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
27. Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis*: A Double-Blind, Placebo-Controlled Multicenter Study
28. Formoterol Turbuhaler® 4.5 μg (Delivered Dose) has a Rapid Onset and 12-h Duration of Bronchodilation
29. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
30. Glucocorticosteroids and pulmonary sarcoidosis
31. Effect of Early vs Late Intervention With Inhaled Corticosteroids in Asthma*
32. Comparison of a β2-Agonist, Terbutaline, with an Inhaled Corticosteroid, Budesonide, in Newly Detected Asthma
33. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions
34. SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility—A Joint Analysis in Four European Populations
35. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data
36. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data
37. Colaboradores
38. Capítulo 1 - Modelo de manejo en la población del asma y la alergia: el caso de Finlandia
39. National and regional asthma programmes in Europe
40. Revisiting early intervention in adult asthma
41. 北海道とフィンランドのサルコイドーシス : 比較研究の結果
42. Steroid-Sparing Strategies: Long-Acting Inhaledβ2-Agonists
43. Corticosteroids
44. Diffuse Lung Disease
45. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD : a double-blind, randomised, non-inferiority, parallel-group, multicentre study
46. Major histocompatibility complex class II andBTNL2associations in sarcoidosis: Table 1–
47. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
48. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis
49. Continuous versus intermittent inhaled corticosteroid (budesonide) for mild persistent asthma in children—not too much, not too little: Figure 1
50. Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.